TY  - JOUR
AU  - Langen, K. J.
AU  - Tonn, J. C.
AU  - Weller, M.
AU  - Galldiks, N.
TI  - Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]
JO  - Journal of neuro-oncology
VL  - 120
IS  - 3
SN  - 0167-594x
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - FZJ-2014-04588
SP  - 665-666
PY  - 2014
AB  - o the Editor,We have read with interest the review by Ryken et al. about the role of imaging in the management of progressive glioblastoma [1]. In general, we agree with this review but we cannot support the opinion that the routine use of Positron-Emission-Tomography (PET) to identify progression of glioblastoma is not recommendable.The authors have considered PET using the amino acid tracer 11C-methyl-l-methionine (MET), but the use of MET is limited to PET centers with an on-site cyclotron due the short half-life of 11C (20.4 min). In recent years, the clinical application of 18F-labeled amino acids such as O-(2-18F-fluoroethyl)-l-tyrosine (FET) or 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine (FDOPA) has spread considerably due to the logistical advantages of the 18F label (half-life, 109.8 min) [2]. FET can be produced with high yields similar to the widely used FDG and distributed in a satellite concept [3]. In Europe, MET PET has been replaced in many centers by the more convenie ...
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000345286700028
DO  - DOI:10.1007/s11060-014-1594-z
UR  - https://juser.fz-juelich.de/record/155422
ER  -